Tharimmune, Inc. (NASDAQ:THAR), a clinical-stage biotechnology company advancing novel solutions in immunology and oncology, today announced the appointment of Vincent LoPriore, Founder of Gravitas ...

Initiation by Merck of a Phase 2 trial in Alzheimer’s disease with partnered α7 nicotinic acetylcholine receptor PAM MK-1167 highlights company’s ...

It is time to showcase the names and faces of the future who are set to shape and define the technology sector in 2025, and ...

As nearly 800,000 Americans face death or permanent disability each year due to diagnostic errors?with women and minorities 30% more likely to be misdiagnosed than white men?it's clear that the U.S.

Who will benefit most from a new UK-US trade deal? - NEWS ANALYSIS: Vice-president JD Vance has said there is a ‘good chance’ ...